| 1. |
Tian S, Xu B, Liu Z, et al. Autoimmune polyglandular syndrome type Ⅲ associated with antineutrophil cytoplasmic autoantibody-mediated crescentic glomerulonephritis[J]. Medicine, 2020, 99(7): e19179[2020-02-01]. http://europepmc.org/article/MED/32049851. DOI: 10.1097/MD.0000000000019179.
|
| 2. |
Zhang L, Barker JM, Babu S, et al. A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type Ⅰ[J]. Clin Immunol, 2007, 125(2): 131-137. DOI: 10.1016/j.clim.2007.07.015.
|
| 3. |
Amerio P, Di Rollo D, Carbone A, et al. Polyglandular autoimmune diseases in a dermatological clinical setting: vitiligo-associated autoimmune diseases[J]. Eur J Dermatol, 2010, 20(3): 354-358. DOI: 10.1684/ejd.2009.0939.
|
| 4. |
Silpa-Archa S, Silpa-Archa N, Preble JM, et al. Vogt-Koyanagi-Harada syndrome: perspectives for immunogenetics, multimodal imaging, and therapeutic options[J]. Autoimmun Rev, 2016, 15(8): 809-819. DOI: 10.1016/j.autrev.2016.04.001.
|
| 5. |
Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis[J/OL]. Nat Rev Dis Primers, 2019, 5(1): 30[2019-05-02]. https://www.nature.com/articles/s41572-019-0079-y. DOI: 10.1038/s41572-019-0079-y.
|
| 6. |
Maurizio C. Autoimmune polyendocrine syndromes[J]. Autoimmun Rev, 2014, 13(2): 85-89. DOI: 10.1016/j.autrev.2013.07.006.
|
